Social Anxiety Disorder Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Condition: Social Anxiety Disorder Interventions: Drug: 225 mg BNC210; Drug: 675 mg BNC210; Drug: Placebo Sponsor: Bionomics Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 14, 2022 Category: Research Source Type: clinical trials
Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
EASTWOOD, Australia, Jan. 3, 2022,.Bionomics Limited (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical trial (the PREVAIL Study) to evaluate BNC210 for the acute... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2022 Category: Pharmaceuticals Source Type: clinical trials
Evaluation of a Self-Monitoring Intervention to Reduce Safety Behavior in Social Anxiety
Condition: Social Anxiety Interventions: Behavioral: Safety Behavior Fading for Social Anxiety; Behavioral: Unhealthy Behavior Fading Sponsor: Florida State University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2021 Category: Research Source Type: clinical trials
